Overview
An anthracenedione-derived antineoplastic agent.
Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Associated Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia
- Acute Promyelocytic Leukemia
- Hodgkin's Lymphoma
- Metastatic Breast Cancer
- Non-Hodgkin's Lymphoma (NHL)
- Progressive Relapsing Multiple Sclerosis
- Relapsed Leukemia
- Relapsed Lymphomas
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
- Hormone refractory, advanced Prostate cancer
- Relapsed Hepatocellular carcinoma
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/03/24 | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | ||
2025/01/07 | Phase 2 | Not yet recruiting | |||
2024/10/01 | Not Applicable | Recruiting | First Affiliated Hospital of Zhejiang University | ||
2024/10/01 | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | ||
2024/09/19 | Phase 1 | Recruiting | |||
2024/07/23 | Phase 2 | Recruiting | Yizhuo Zhang | ||
2024/07/12 | Early Phase 1 | Recruiting | BGI, China | ||
2024/07/08 | Phase 2 | Recruiting | |||
2024/06/25 | Phase 2 | Recruiting | Ming-Yuan Chen | ||
2024/06/06 | Phase 2 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Hospira, Inc. | 61703-343 | INTRAVENOUS | 2 mg in 1 mL | 4/15/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| MITOXANTRONE BAXTER INJECTION 2 mg/ml | SIN11629P | INJECTION | 2 mg/ml | 8/15/2001 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Mitoxantrone Hydrochloride Liposome Injection | 国药准字H20220001 | 化学药品 | 注射剂 | 1/7/2022 | |
| Mitoxantrone Hydrochloride Sodium Chloride Injection | 国药准字H10980248 | 化学药品 | 注射剂(注射液) | 12/2/2020 | |
| Mitoxantrone Hydrochloride for Injection | 国药准字H10960120 | 化学药品 | 注射剂(冻干) | 6/1/2020 | |
| Mitoxantrone Hydrochloride for Injection | 国药准字H20057796 | 化学药品 | 注射剂 | 7/7/2020 | |
| Mitoxantrone Hydrochloride for Injection | 国药准字H20056427 | 化学药品 | 注射剂(冻干粉针剂) | 5/20/2020 | |
| Mitoxantrone Hydrochloride for Injection | 国药准字H32020964 | 化学药品 | 注射剂 | 8/31/2020 | |
| Mitoxantrone Hydrochloride for Injection | 国药准字H20060894 | 化学药品 | 注射剂 | 1/14/2021 | |
| Mitoxantrone Hydrochloride for Injection | 国药准字H20093281 | 化学药品 | 注射剂 | 6/17/2020 | |
| Mitoxantrone Hydrochloride Injection | 国药准字H10960192 | 化学药品 | 注射剂(注射液) | 12/10/2020 | |
| Mitoxantrone Hydrochloride Injection | 国药准字H10960190 | 化学药品 | 注射剂(注射液) | 12/10/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Help Us Improve
Your feedback helps us provide better drug information and insights.